About the Company
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CCXI News
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the ...
US Physical Therapy Stock (NYSE:USPH), Quotes and News Summary
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per ...
Rishi Gupta's Net Worth
Rishi Gupta has an estimated net worth of $347 Million. This is based on reported shares across multiple companies, which include ChemoCentryx, Inc., Turnstone Biologics Corp., Verona Pharma plc ...
Inflation Problems Persist And AI Makes Headlines: Forbes AI Newsletter - September 17th
Earnings per share have grown 11.68% over the past 12 months. Chemocentryx Inc – The biotech company is one of our Top Shorts for next month with our AI rating them an F in our Low Momentum ...
Federal Reserve Continues Interest Rate Hikes And Housing Market Sees Spike In Mortgage Rates: Forbes AI Newsletter - September 24th
Earnings per share have grown 8.78% over the past 12 months. Chemocentryx Inc (CCXI) – The biotech company remains one of our Top Shorts for next month with our AI rating them an F in our Low ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Snap Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Block Inc.
1 Day SQ -1.32% DJIA -0.49% S&P 500 -0.65% Technology -1.75% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...
Apple Inc.
1 Day AAPL 2.56% DJIA 0.30% S&P 500 1.05% Technology -1.75% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Former Chairman, CEO and Founder of ChemoCentryx, Inc. CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop ...
Loading the latest forecasts...